There are 2789 resources available
316P - Attitudes towards the use of stereotactic body radiation therapy in oligometastatic breast cancer: Results of an OncoAlert survey
Presenter: Petra Vukovic
Session: ePoster Display
317P - Survival analysis and prognostic factors in patients with metastatic breast cancer and oligometastatic disease
Presenter: Gema Marin Zafra
Session: ePoster Display
425P - Cetuximab could be administered once every two weeks instead of once weekly
Presenter: sarah Lobet
Session: ePoster Display
426P - Spotlight on refractory metastatic colorectal cancer (refMCRC): Role of prognostic characteristics in the continuum of care
Presenter: Augusto Valdivia
Session: ePoster Display
427P - Real world data of trifluridine/tipiracil in refractory mCRC: A multicenter experience at four GEODA Spanish hospitals
Presenter: Julia Martinez Perez
Session: ePoster Display
428P - Retrospective cohort study of low-dose apatinib plus S-1 versus regorafenib and fruquintinib for refractory metastatic colorectal cancer
Presenter: Hong Qiu
Session: ePoster Display
Resources:
Abstract
430P - Learning from FOCUS4: A molecularly stratified adaptive trial platform in metastatic colorectal cancer
Presenter: Janet Graham
Session: ePoster Display
Resources:
Abstract
308P - FDG-PET/CT versus CE-CT for response monitoring in metastatic breast cancer: A prospective comparative study
Presenter: Marianne Vogsen
Session: ePoster Display
309P - Antineoplastic (ANP) therapies (Tx) after alpelisib (ALP) or placebo (PBO) + fulvestrant (FUL) in patients (Pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (Mut) advanced breast cancer (ABC): An analysis from SOLAR-1
Presenter: Fabrice André
Session: ePoster Display